Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release May 22 2024

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has announced that it received final approval from the USFDA for Theophylline Extended-Release Tablets in two dosages. This medication is intended for the treatment of asthma and chronic obstructive pulmonary disease. The tablets will be manufactured at Zydus's facility in Ahmedabad SEZ, India.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 22, 2024, titled "Zydus receives final approval from USFDA for Theophylline Extended-Release Tablets, 300 mg and 450 mg".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases